GSK's investigational vaccine 692342

Phase 3Vaccine

GSK's investigational vaccine 692342 is one of 105 biologic programs targeting Typhoid Fever. It is currently in Phase 3.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

Typhoid FeverActive, not recruiting

ImmunodeficiencyActive, not recruiting

InfluenzaActive, not recruiting

TuberculosisActive, not recruiting

ShigellosisActive, not recruiting

Typhoid FeverPhase 1/Phase 2

Active, not recruiting

ImmunodeficiencyPhase 2

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

TuberculosisPhase 2

Active, not recruiting

ShigellosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

GSK's investigational vaccine 692342

GSK

Phase 3

1 2

Fluzone

Sanofi

Preclinical

16 3

Crestor

AstraZeneca

Preclinical

1 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 9

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tuberculosis5 trials

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

Completed· GSK logo

GSK·Phase 2·NCT01098474·301 enrolled

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents

Completed· GSK logo

GSK·Phase 2·NCT00950612·60 enrolled

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.

Completed· GSK logo

GSK·Phase 2·NCT00707967·37 enrolled

Show 2 more trials

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

Completed· GSK logo

GSK·Phase 2·NCT00397943·110 enrolled

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

Completed· GSK logo

GSK·Phase 1·NCT00730795·12 enrolled

Influenza1 trial

A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine

Withdrawn· GSK logo

GSK·Phase 3·NCT00866580

Typhoid Fever1 trial

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever

Completed· GSK logo

GSK·Phase 1/2·NCT05480800·155 enrolled

Respiratory Syncytial Virus (RSV)1 trial

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Completed· GSK logo

GSK·Phase 1/2·NCT03636906·201 enrolled

Immunodeficiency1 trial

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults

Completed· GSK logo

GSK·Phase 2·NCT01262976·240 enrolled

1 more indication

Diarrhoea1 trial

A Staged Phase I/II Observer-blind, Randomised, Controlled, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against S. Sonnei and S. Flexneri, Serotypes 1b, 2a, and 3a, in Adults in Europe (Stage 1) Followed by Age De-escalation From Adults to Children and Infants, and Dose-finding in Infants in Africa (Stage 2)

Completed· GSK logo

GSK·Preclinical·NCT05073003·551 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for GSK's investigational vaccine 692342. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK's investigational vaccine 692342 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK's investigational vaccine 692342. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: GSK

GSK's investigational vaccine 692342

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tuberculosis5 trials

Influenza1 trial

Typhoid Fever1 trial

Respiratory Syncytial Virus (RSV)1 trial

Immunodeficiency1 trial

Diarrhoea1 trial

References

Drug Info

Quick Facts

Related News